BioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on Monday

BioCryst Pharmaceuticals (NASDAQ:BCRX) is expected to post its Q2 2025 quarterly earnings results before the market opens on Monday, August 4th. Analysts expect BioCryst Pharmaceuticals to post earnings of $0.02 per share and revenue of $149.59 million for the quarter.

BioCryst Pharmaceuticals Stock Down 2.3%

BioCryst Pharmaceuticals stock opened at $7.95 on Friday. BioCryst Pharmaceuticals has a 52 week low of $6.01 and a 52 week high of $11.31. The business has a 50-day simple moving average of $9.54 and a 200 day simple moving average of $8.72. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -30.58, a PEG ratio of 1.33 and a beta of 1.10.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in BCRX. Caxton Associates LLP bought a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter valued at about $314,000. Royal Bank of Canada lifted its stake in shares of BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after acquiring an additional 1,458 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of BioCryst Pharmaceuticals by 6.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock valued at $1,019,000 after acquiring an additional 8,517 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of BioCryst Pharmaceuticals by 11.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock valued at $3,363,000 after acquiring an additional 47,355 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 49.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock valued at $14,490,000 after acquiring an additional 640,704 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Wedbush boosted their target price on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an “outperform” rating in a research report on Monday, June 30th. Bank of America boosted their target price on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, July 1st. Wall Street Zen upgraded BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 26th. Finally, Cantor Fitzgerald began coverage on BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They set an “overweight” rating and a $20.00 price target for the company. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $16.70.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.